Aethlon Medical Reports Q2 Cost Reduction and Ongoing Cancer Trial Progress

Reuters

Nov 13

Aethlon Medical Reports <a href="https://laohu8.com/S/QTWO">Q2</a> Cost Reduction and Ongoing Cancer Trial Progress

Aethlon Medical Inc. reported financial results for its fiscal second quarter ended September 30, 2025. The company announced a 48% reduction in operating expenses, reflecting ongoing cost management efforts. As of September 30, 2025, Aethlon held a cash balance of approximately $5.8 million. The company confirmed it has resolved Nasdaq compliance matters and remains listed on the Capital Market. Operationally, recruitment is underway for Cohort 2 of the Australian oncology trial under an amended protocol. Aethlon also continues its collaboration with UCSF on Long COVID research, with a manuscript in preparation for a peer-reviewed journal. Additionally, the company initiated evaluation of its Hemopurifier device compatibility with a simplified blood treatment system.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA22014) on November 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2583583813"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583583813\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583583813?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583583813","market":"us","top_or_hot":-1,"title":"Aethlon Medical Reports Q2 Cost Reduction and Ongoing Cancer Trial Progress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aethlon Medical Reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> Cost Reduction and Ongoing Cancer Trial Progress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AEMD\">Aethlon Medical Inc</a>. reported financial results for its fiscal second quarter ended September 30, 2025. The company announced a 48% reduction in operating expenses, reflecting ongoing cost management efforts. As of September 30, 2025, Aethlon held a cash balance of approximately $5.8 million. The company confirmed it has resolved Nasdaq compliance matters and remains listed on the Capital Market. Operationally, recruitment is underway for Cohort 2 of the Australian oncology trial under an amended protocol. Aethlon also continues its collaboration with UCSF on Long COVID research, with a manuscript in preparation for a peer-reviewed journal. Additionally, the company initiated evaluation of its Hemopurifier device compatibility with a simplified blood treatment system.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA22014) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aethlon Medical Reports Q2 Cost Reduction and Ongoing Cancer Trial Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAethlon Medical Reports Q2 Cost Reduction and Ongoing Cancer Trial Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 05:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aethlon Medical Reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> Cost Reduction and Ongoing Cancer Trial Progress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AEMD\">Aethlon Medical Inc</a>. reported financial results for its fiscal second quarter ended September 30, 2025. The company announced a 48% reduction in operating expenses, reflecting ongoing cost management efforts. As of September 30, 2025, Aethlon held a cash balance of approximately $5.8 million. The company confirmed it has resolved Nasdaq compliance matters and remains listed on the Capital Market. Operationally, recruitment is underway for Cohort 2 of the Australian oncology trial under an amended protocol. Aethlon also continues its collaboration with UCSF on Long COVID research, with a manuscript in preparation for a peer-reviewed journal. Additionally, the company initiated evaluation of its Hemopurifier device compatibility with a simplified blood treatment system.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA22014) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AEMD","symbol_name":"Aethlon Medical Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLbhZgRc:1","article_id":"2583583813","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583583813","pubTimestamp":1762982197,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aethlon Medical Inc. reported financial results for its fiscal second quarter ended September 30, 2025. The company announced a 48% reduction in operating expenses, reflecting ongoing cost management efforts. As of September 30, 2025, Aethlon held a cash balance of approximately $5.8 million. The company confirmed it has resolved Nasdaq compliance matters and remains listed on the Capital Market. Operationally, recruitment is underway for Cohort 2 of the Australian oncology trial under an amended protocol. Aethlon also continues its collaboration with UCSF on Long COVID research, with a manuscript in preparation for a peer-reviewed journal. Additionally, the company initiated evaluation of its Hemopurifier device compatibility with a simplified blood treatment system.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AEMD":"Aethlon Medical Inc","BK4568":"美国抗疫概念","BK4082":"医疗保健设备","BK4583":"猴痘概念"},"translate_title":"Aethlon Medical报告第二季度成本降低和正在进行的癌症试验进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEMD":0.9},"content_text":"Aethlon Medical Reports Q2 Cost Reduction and Ongoing Cancer Trial Progress\n    \n\nAethlon Medical Inc. reported financial results for its fiscal second quarter ended September 30, 2025. The company announced a 48% reduction in operating expenses, reflecting ongoing cost management efforts. As of September 30, 2025, Aethlon held a cash balance of approximately $5.8 million. The company confirmed it has resolved Nasdaq compliance matters and remains listed on the Capital Market. Operationally, recruitment is underway for Cohort 2 of the Australian oncology trial under an amended protocol. Aethlon also continues its collaboration with UCSF on Long COVID research, with a manuscript in preparation for a peer-reviewed journal. Additionally, the company initiated evaluation of its Hemopurifier device compatibility with a simplified blood treatment system.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA22014) on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}